U.S. Imposes New Section 232 Tariffs on Patented Pharmaceuticals and APIs
Dear Clients,
On April 2, 2026, President Trump issued a Presidential Proclamation titled “Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States,” establishing a new tariff regime under Section 232 of the Trade Expansion Act of 1962 for certain imported patented pharmaceuticals and Active Pharmaceutical Ingredients.
The new measures may have significant implications for Israeli pharmaceutical and life sciences companies with U.S. market exposure, including in relation to supply chain planning, pricing, and manufacturing strategy.
In this client update, we outline the main elements of the new regime and highlight several practical considerations for Israeli pharmaceutical and life sciences companies exporting to the United States, manufacturing products for the U.S. market, or otherwise involved in supplying pharmaceutical products to the United States.
As always, the team at Agmon with Tulchinsky remains at your disposal.
More Relevant Media
12.03.2026
AI in Drug Development, Biologics, and Medical Devices: Recent Signals from the FDA and EMA
Client updates
08.02.2026
AI in Clinical Trials, Moving from Pilot to Scale and the Trust Gap That Still Holds It Back
Client updates
20.01.2026
Reported Patient Death in an Innovative CRISPR Trial – Client Update – January 2026
Client updates
15.01.2026
Reported Merck Interest in Revolution Medicines – Market Signals for 2026 Biotech M&A Deal Structures and Negotiation Strategy
Client updates